Business
New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy
Duchenne muscular dystrophy is a rare, debilitating and life-shortening neuromuscular disease1Upon approval, vamorolone would be the first and only treatment
About this update from Catalyst Pharmaceuticals, Inc.
[{"type":"text","content":"Duchenne muscular dystrophy is a rare, debilitating and life-shortening neuromuscular disease1Upon approval, vamorolone would be the first and only treatment option indicated for patients diagnosed with Duchenne muscular dystrophy in CanadaThe Canadian regulatory submission of vamorolone follows approvals in the US in 2023, and the European Union in early 2024This New Drug Submission reflects Kye Pharmaceuticals' commitment to advancing treatments for rare diseases and serving the unmet needs of Canadian patientsMISSISSAUGA, ON, April 8, 2025 /PRNewswire/ - Kye Pharmaceuticals, Inc. (\"Kye\") announced today it has submitted a New Drug Submission (NDS) to Health Canada for the regulatory review and approval of AGAMREE® (vamorolone). If approved, AGAMREE® would be the first and only therapy approved by Health Canada with an indication for the treatment of Duchenne muscular dystrophy (DMD). Health Canada has granted AGAMREE® a priority review and marketing authorization could be granted before the end of 2025. News of the AGAMREE® priority review was welcomed by national patient organizations.\n\n \n \n \n \n \n \n\n \n\"Defeat Duchenne Canada is thrilled that Health Canada has accepted AGAMREE® for priority review. There are currently no approved treatments available in Canada for young people living with Duchenne muscular dystrophy. We urge Health Canada to approve AGAMREE® to ensure all Canadians for whom this treatment would be beneficial, can access it as soon as possible.\" Lisa McCoy, Chief Executive Officer, Defeat Duchenne.\n\"Muscular Dystrophy Canada (MDC) is pleased that Health Canada has granted Priority Review for AGAMREE® (vamorolone). While corticosteroids have been a key treatment for decades, they are not currently approved for DMD, and their significant side effects have been a challenge for the Duchenne muscular dystrophy community. If approved, this promising treatment will provide options for the Duchenne muscular dystrophy community.\" Stacey Lintern, Chief Executive Officer, MDC.\nThe Canadian Neuromuscular Disease registry estimates that there are more than 800 boys and young men living with DMD in Canada and coping with its debilitating symptoms.2 Duchenne muscular dystrophy (DMD) is a type of muscular dystrophy that causes weakness and a wasting of the muscle due to the absence of a protein called dystro...